We have a License Agreement with Allogene Therapeutics, Inc., according to which we granted to Allogene an exclusive, worldwide license to develop and commercialize CAR T-cell products directed at a total of 15 selected targets* (including BCMA and CD70).

Financials: 

Up to $2.8B In Development & Sales Milestones ​+ High Single-Digit Royalties on Sales 

(*) Servier grants to Allogene exclusive rights to cemacabtagene ansegedleucel (cema-cel) in the U.S., EU and UK.

We have a License, Development and Commercialization Agreement with Les Laboratoires Servier, according to which Servier has an exclusive worldwide license to develop and commercialize gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501 and ALLO-501A. 

Cema-cel is a product candidate licensed to Servier under the License, Development and Commercialization Agreement signed by and between les Laboratoires Servier and Institut de Recherches Internationales Servier (“Servier”) and Cellectis (the “Servier Agreement”) and sublicenced by Servier to Allogene in certain territories*.  

Financials: 

Up to $340M In Development & Sales Milestones + Low Double-Digit Royalties on Net Sales of Licensed CD19 Products, Including Cema-cel Developed in LBCL. 

(*) Servier grants to Allogene exclusive rights to cemacabtagene ansegedleucel (cema-cel) in the U.S., EU and UK.

We have a research collaboration and exclusive worldwide license agreement with Iovance Biotherapeutics, Inc. enabling Iovance to use certain TALEN® technology addressing multiple gene targets to modify tumor-infiltrating lymphocytes (TIL) for therapeutic use in several cancer indications. 

Financials: 

Undisclosed 

We have a joint Research and Collaboration agreement to develop up to 10 novel products in oncology, immunology and rare diseases and investment agreement 

Financials:

Up to $80M to $253M Per Product in Milestones + Tiered Royalties. $220M Equity Investment and $25m Upfront.